Remedee Labs
Remedee Labs is a French medical device company that has developed a CE-marked millimeter wave neuromodulation wristband to trigger endorphin release, marketed via monthly subscription as FibroRem for fibromyalgia patients and NoviRem for osteoarthritis patients in metropolitan France.
- Company typePrivate
- Founded2016
- HeadquartersMontbonnot-saint-martin, France
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Remedee Labs does
Remedee Labs SA is a French medical device company founded in 2016 and headquartered in Meylan, near Grenoble, that has developed a proprietary millimeter wave neuromodulation platform delivered through a wearable wristband. The core technology centers on the patented MEET (Microelectronic Endorphin Trigger) module, a silicon-based microelectronic component emitting 61 GHz millimeter waves that penetrate less than 0.5 mm into the skin at the wrist to stimulate peripheral nerve endings and trigger intracerebral endorphin release, modulating central nervous system pain perception. The platform has received CE Class IIa medical device certification for fibromyalgia (September 2024) and osteoarthritis (April 2025), plus FDA Breakthrough Device Designation for fibromyalgia (May 2022), making it the first medical device specifically authorized in Europe for fibromyalgia treatment.
The company markets two consumer-facing therapeutic solutions: FibroRem for fibromyalgia patients and NoviRem for osteoarthritis patients, each priced at €49.90 per month under a no-commitment subscription that bundles the Remedee wristband, the myRemedee companion mobile application for symptom tracking and adherence, and human coaching support. Distribution is exclusively direct-to-consumer through dedicated websites (fibrorem.com and novirem.com), currently limited to metropolitan France, with a parallel healthcare professional channel operated through a partnership with pharmaceutical company UPSA whose medical representatives introduce the technology to pain specialists and rheumatologists. Revenue is entirely recurring subscription-based with no pharmacy retail or Social Security reimbursement currently in place, though HAS evaluation for potential future reimbursement has been initiated.
Remedee Labs has raised approximately €23.2 million across seed and Series A rounds, with Generali France as the lead strategic investor in the Series A. Clinical validation rests on two trials (FIBREPIK and EPIKARTHROSE) conducted across eight French pain centers, supported by real-world evidence on more than 5,000 fibromyalgia and 2,000 osteoarthritis users, with efficacy outcomes including 33.9% pain intensity reduction in osteoarthritis and 62.3% of fibromyalgia patients achieving clinically significant FIQ improvement. The company employs approximately 30 people across medical research, microelectronics, software development, and artificial intelligence disciplines, with leadership combining biomedical research, semiconductor architecture, and scaling expertise from prior roles at CEA-Clinatec, SIGFOX, and Sanofi.
Remedee Labs firmographics
Firmographics- Name
- Remedee Labs
- Legal name
- Remedee Labs SA
- Website
- https://remedeelabs.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Remedee Labs is a French medical device company that has developed a CE-marked millimeter wave neuromodulation wristband to trigger endorphin release, marketed via monthly subscription as FibroRem for fibromyalgia patients and NoviRem for osteoarthritis patients in metropolitan France.
- Ownership category
- akta.pro rank
Remedee Labs industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industries
- Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Chronic Pain Rehabilitation & Functional Restoration (HSADAIAJ)
Keywords
Where Remedee Labs is headquartered
LocationHeadquarters
- HQ city
- Montbonnot-saint-martin
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Remedee Labs business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Monthly Subscription (Hardware + Software + Support): Recurring monthly subscription model at €49.90 per month providing access to the Remedee wristband device, myRemedee application, human coaching support, and personalized follow-up. No commitment duration - subscription can be cancelled at any time. Revenue is entirely recurring as customers maintain ongoing subscriptions for chronic pain management.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Single subscription tier for all solutions |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Remedee Labs product offering
Product offeringCore offering
Remedee Labs develops and sells a CE-marked Class IIa wearable medical wristband that uses 61 GHz millimeter wave neuromodulation to stimulate peripheral nerve endings and trigger intracerebral endorphin release for non-pharmacological chronic pain management. The hardware is bundled with the myRemedee companion mobile application and personalized human coaching, and is marketed as two condition-specific subscriptions: FibroRem for fibromyalgia and NoviRem for osteoarthritis, priced at €49.90 per month with no commitment.
Product overview
Remedee Labs offers a platform of connected healthcare solutions based on its proprietary millimeter wave neuromodulation technology. The core offering consists of the Remedee™ endorphin stimulator wristband paired with the myRemedee™ mobile application. The company markets two specialized therapeutic solutions: FibroRem™ for fibromyalgia (the first CE-marked medical device for this condition in Europe) and NoviRem™ for osteoarthritis (also CE-marked). Both solutions combine the wearable device, a companion smartphone app, personalized human coaching, and educational content as part of a comprehensive biopsychosocial approach to chronic pain management. The underlying MEET (Microelectronic Endorphin Trigger) module is protected by 12+ international patents.
Differentiator
Problem solved
Functional benefit
Brands
- FibroRem: First CE-marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe. Solution includes the Remedee endorphin-stimulating wristband combined with a comprehensive support program for fibromyalgia patients.
- NoviRem
Quantifiable outcome
- 21% reduction in pain intensity (VAS score) for osteoarthritis patients after 3 months
- +7 more outcomes
Companies that use Remedee Labs
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Remedee Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Remedee Labs partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- STMicroelectronicscoreTechnology partnership with STMicroelectronics for excellence in French healthcare technology. STMicroelectronics supplies semiconductor components for the MEET module, enabling the miniaturized millimeter wave neuromodulation technology.
- UPSAcorePartnership between French pharmaceutical company UPSA and Remedee Labs to bring comprehensive chronic pain management to healthcare professionals and their patients. UPSA medical representatives present Remedee Labs' technology to healthcare professionals as part of the partnership.
- Future4CareminorIntegration into Future4Care digital health startup accelerator, providing support for startup development and growth in the digital health sector.
- CEA ClinateccoreResearch partnership with CEA Clinatec (Grenoble) for MEG study on endorphin release measurement and clinical validation of millimeter wave therapy technology.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Remedee Labs competitors and assessment
Company assessmentDirect peers
- NeuroMetrix (Quell): Developer of Quell, a wearable transcutaneous electrical nerve stimulation (TENS) device for chronic pain management. Competes directly with Remedee in the non-invasive, wearable, drug-free chronic pain neuromodulation category targeting similar patient profiles.
- Cefaly Technology: Maker of the Cefaly device, a wearable external trigeminal nerve stimulation device for migraine prevention and treatment. Directly comparable to Remedee as a small, wearable, CE-marked neuromodulation device sold direct-to-consumer for chronic pain indications.
- Cala Health: Developer of Cala Trio and Cala kIQ, wearable transcutaneous afferent patterned stimulation (TAPS) devices for essential tremor and other chronic conditions. Closely comparable business model: small wearable neuromodulation device with companion app, sold direct-to-consumer for chronic neurological conditions.
- Hinge Health: Digital musculoskeletal pain management platform combining app-based exercise therapy with wearable sensors and remote coaches. Competes with Remedee for the same chronic pain patient population (especially osteoarthritis and fibromyalgia) using a digital + coaching approach with subscription pricing.
Emerging players
- SPR Therapeutics: Developer of minimally invasive peripheral nerve stimulation (PNS) systems for chronic and acute pain. Comparable therapeutic area (chronic pain neuromodulation) but distinct delivery mechanism (implantable vs. Remedee's non-invasive wristband).
- Saluda Medical: Developer of the Evoke closed-loop spinal cord stimulation system for chronic pain management. Comparable in neuromodulation therapeutic area but operates in the implantable device category versus Remedee's non-invasive wearable approach.
- Kaia Health: Digital therapeutics company offering app-based programs for chronic pain (including back pain and osteoarthritis) via exercise, education and behavioral coaching. Competes for the same chronic pain patient population with a software-only approach versus Remedee's hardware + software combination.
- Bosana Medizintechnik (Stimulette / Curon): European medical device companies offering TENS and other electrical stimulation devices for pain management. Adjacent players in the non-invasive electrotherapy category competing for similar patient and HCP customers in European markets.
Broad incumbents
- Medtronic (Pain Therapies division): Global leader in implantable neurostimulation devices for chronic pain (including Intellis and Vanta platforms). Represents the dominant incumbent in the broader neuromodulation pain market and a key competitor Remedee must differentiate against; notably, Remedee's advisor Julie Foster was previously GM of Medtronic Pain Therapies.
- Abbott (Neuromodulation division): Major incumbent offering the Proclaim XR and Eterna spinal cord stimulation systems for chronic pain, plus dorsal root ganglion stimulation. Competes in the broader chronic pain neuromodulation market with much broader portfolio and HCP channel depth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Remedee Labs social profiles
Digital presenceRemedee Labs compliance and trust
Trust signalCompliance3 records
Remedee Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Remedee Labs leadership team
Management profileNumber of profiles
Profiles6 records
Remedee Labs funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Remedee Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Remedee Labs
What does Remedee Labs do?
Remedee Labs develops and sells a CE-marked Class IIa wearable medical wristband that uses 61 GHz millimeter wave neuromodulation to stimulate peripheral nerve endings and trigger intracerebral endorphin release for non-pharmacological chronic pain management. The hardware is bundled with the myRemedee companion mobile application and personalized human coaching, and is marketed as two condition-specific subscriptions: FibroRem for fibromyalgia and NoviRem for osteoarthritis, priced at €49.90 per month with no commitment.
Is Remedee Labs a public or private company?
Remedee Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Remedee Labs founded?
Remedee Labs was founded in 2016. It employs 11 to 50 people.
Where is Remedee Labs based?
Remedee Labs is headquartered in Montbonnot-saint-martin, France, in the Europe region.
How does Remedee Labs make money?
One revenue line is on record: monthly Subscription (Hardware + Software + Support).
Who are Remedee Labs's main competitors?
Direct peers on record are NeuroMetrix (Quell), Cefaly Technology, Cala Health and Hinge Health. Emerging players are SPR Therapeutics, Saluda Medical, Kaia Health and Bosana Medizintechnik (Stimulette / Curon). Broad incumbents are Medtronic (Pain Therapies division) and Abbott (Neuromodulation division).
Does Remedee Labs have an API?
No public API is recorded for Remedee Labs.
What industry is Remedee Labs in?
Remedee Labs's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLALABAK, Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms. Its NAICS code is 334510 and its SIC code is 3845.